FIELD: pharmaceuticals.
SUBSTANCE: invention relates to an application of a JNK (c-Jun N-terminal kinase) inhibitor sodium 11H-indeno[1,2-b]quinoxaline-11-onoxime as a venlafaxine metabolism inducer, which can be used to personalise and increase the effectiveness of antidepressant therapy, in particular, to increase the level of intensity of drug transformation in weak venlafaxine metabolisers (persons with a low expression of CYP2D6 or patients with liver diseases) up to the normal level.
EFFECT: effective induction (stimulation) of venlafaxine metabolism.
1 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR STIMULATION OF GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTION BY BONE MARROW CELLS IN VITRO | 2020 |
|
RU2741784C1 |
| METHOD FOR STIMULATING PRODUCTION OF GRANULOCYTE COLONY-STIMULATING FACTOR BY BONE MARROW CELLS IN VITRO | 2021 |
|
RU2770784C1 |
| METHOD FOR STIMULATION OF ERYTHROPOIETIN PRODUCTION BY BONE MARROW CELLS IN VITRO | 2019 |
|
RU2713122C1 |
| HEMOSTIMULATING AGENT | 2017 |
|
RU2647833C1 |
| GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION | 2013 |
|
RU2683260C2 |
| AGENT POSSESSING HYPOLIPIDEMIC ACTIVITY | 2020 |
|
RU2732503C1 |
| METHOD FOR PREDICTING SIDE EFFECTS ASSOCIATED WITH HORMONAL CONTRACEPTION | 2014 |
|
RU2552335C1 |
| METHOD OF DETERMINING POLYMORPHIC MARKERS IN CYP2C19 AND CYP2D6 GENES FOR DETERMINING INDIVIDUAL SENSITIVITY TO ANTIDEPRESSANTS | 2018 |
|
RU2716589C1 |
| ENZYME ELECTRODE FOR DETERMINING AMINOPYRINE CONTENT IN AQUEOUS SOLUTION, METHOD FOR PRODUCING AND DETERMINING AMINOPYRINE IN AQUEOUS SOLUTION | 2001 |
|
RU2213346C2 |
| METHOD FOR DETERMINING HUMAN GENOTYPE BY POLYMORPHISM IN THE CYTOCHROME GENE P450 CYP2D6*9 (2615-2617DELAAG) RS5030656 | 2016 |
|
RU2651773C2 |
